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Action on diabetic macular oedema:
achieving optimal patient management in
treating visual impairment due to diabetic
eye disease
Introduction
Diabetes has been estimated to affect over 8% of the
world’s population and, as a signiﬁcant cause of mortality
and major morbidity, is now posing one of the greatest
challenges for our healthcare systems.1,2 The global
prevalence of diabetes is set to double over the next
20 years, with the vast majority of this increase related to
type 2 diabetes.1,2 As such, type 2 diabetes is increasingly
recognised as a disease pandemic that is arguably one of
the largest global health emergencies of the 21st century.2
There is therefore an increasing need for knowledge,
skills, resources, and infrastructure to deliver the
comprehensive healthcare needed to meet the complex
demands of this progressive condition. Health policy and
interventions should focus on diabetes prevention and
early detection, including diabetic eye screening, as well
as rehabilitation and long-term care of patients affected by
wide-ranging complications of diabetes, such as end
organ failure, blindness or amputation.
Healthcare professionals often work in isolation to
deliver highly specialised care efﬁciently and effectively
for the individual patient with diabetes and its effects on
multiple organ systems. It is not uncommon for a patient
to be making frequent visits to community clinics and
different hospital clinics to see a variety of specialists and
allied healthcare professionals, with seemingly little
opportunity for coordination of this complex health
management programme between the wider team
involved. In a ﬁeld that is so diverse and rapidly
changing, healthcare professionals of all specialties need
to be aware of developments across all aspects of diabetes
management.
In this article, the authors provide an update for
ophthalmologists and allied healthcare professionals on
diabetes prevalence, the perspective of the diabetologist
on what an ophthalmologist needs to know about
diabetes, including developments and challenges in
diabetic retinopathy screening. In addition, the paper
discusses qualitative research assessment of treatment
adherence and patient experience, the role of the diabetes
specialist nurse (DSN) and practice principles for the
management of people with diabetic eye disease.
Summaries with concise ‘take home’ messages from each
topic are provided to enable the reader to easily focus on
or refer to speciﬁc issues or areas of interest.
Diabetes is an escalating global health challenge
The World Health Organization (WHO) estimates that the
global age-standardised adult prevalence of diabetes has
nearly doubled since 1980, rising from a prevalence rate of
4.7% in 1980 to 8.5% of the adult population in 2014 and
reﬂecting an increase in associated risk factors.1 The rise
in the age-standardised adult prevalence of diabetes is
compounded by population growth and ageing, with
older adults accounting for a larger proportion of the
population in developed countries.3 Type 2 diabetes,
consequent upon complex pathophysiology but
effectively driven by defective energy homoeostasis and
closely linked with obesity (body mass index ≥ 30 kg/m2)
and physical inactivity, accounts for the majority of
people with diabetes worldwide.1
Prevalence data, estimated by the Non-Communicable
Diseases (NCD) Risk Factor Collaboration, were pooled
from population-based studies that had collected data on
diabetes through measurement of its biomarkers to arrive
at estimated trends in diabetes prevalence since 1980.3
Diabetes was deﬁned as fasting plasma glucose (FPG)
≥ 7.0 mmol/L; a history of diagnosis with diabetes; or use
of insulin or oral hypoglycaemic drugs. The International
Diabetes Federation (IDF) estimates there were 415
million adults aged 20–79 years with diabetes worldwide
in 2015, including 193 million undiagnosed (Table 1).2
An estimated 1.5 million deaths in 2012 were directly
caused by diabetes, and another 2.2 million deaths were
attributable to hyperglycaemia.1 Diabetes and the
management of related complications accounted for 12%
of total healthcare expenditure worldwide in 2015, with
over 80% of this expenditure being driven by the costs of
complications.2 The direct annual cost of diabetes in the
world is estimated at US $825 billion based on diabetes
prevalence projections for 2014.3 Three-quarters of the
global expenditure on diabetes was for people aged
between 50 and 79 years, reﬂecting a higher prevalence of
diabetes and of diabetes complications in this burgeoning
age group.2
Prevalence estimates of United Kingdom adult diabetes
approach 1 in 10. The WHO estimates a UK diabetes
prevalence rate of 7.7% in 2014.1 The estimated number of
UK adults with diabetes in 1980 was 2.3 million,
increasing to an estimated 3.8 million adults with diabetes
in 2014.3 Approximately 90% of people with diabetes
have type 2 diabetes.4 Table 2 shows estimates of diabetes
prevalence in the adult population across the United
Kingdom for 2016: 3.6 million people have diagnosed
diabetes and a further 1 million with undiagnosed
diabetes.4
Prevalence estimates prepared by Public Health
England’s National Cardiovascular Intelligence Network
indicate that around 9% of the adult population in
England in 2015 has diabetes and this prevalence rate is
projected to increase to 9.7% by 2035.5 Diabetes
prevalence rates increase with age, from 9.0% for people
aged 45–54 years to 23.8% for people aged 75 years and
older (Figure 1). According to Public Health England, 2%
of adults aged 16–44 years have diabetes, equating to
400 000 people and accounting for 10% of total estimated
diabetes cases.5
Clinical commissioning groups (CCGs) with the highest
estimated diabetes prevalence have high proportions of
South Asian and black ethnic groups and high levels of
deprivation, reﬂecting the well-recognised association
between ethnicity and deprivation with incident diabetes
risk.6,7 The analysis and comparisons with the 2014/15
Quality and Outcomes Framework suggest that 76% of
people with diabetes have been diagnosed and are
included on General Practice (GP) registers, that is, 24% of
people with diabetes are undiagnosed.
G
U
ID
E
L
IN
E
Eye (2017) 31, S1–S20
Ofﬁcial journal of The Royal College of Ophthalmologists
www.nature.com/eye
Hamer et al8 found a nearly doubling in the prevalence
rate of diabetes over the 5-year period between 2003 and
2008 in Scotland, which increased from 5.2% in 2003 to
9.4% in 2008. Imkampe and Gulliford9 similarly identiﬁed
increasing diabetes prevalence rates in United Kingdom.
Prevalence of diagnosed diabetes increased in men from
3.74% in 1994 to 7.25% in 2006 and in women from 2.28 to
4.88% (prevalence based on self-reported diabetes
diagnosed by a doctor). The IDF estimates a diabetes
prevalence rate in Ireland of 5.3% in adults aged 20–79
years in 2015,2 with 171 800 adults having diagnosed
diabetes
Diabetes-related health expenditure in the United
Kingdom was estimated at US $13 billion in 2015.2 The
nation is ranked one of the top ten countries for diabetes-
related healthcare expenditure.2
National Diabetes Audit (United Kingdom and Wales), key
ﬁndings, and recommendations. The National Diabetes
Audit (NDA) provides a comprehensive overview of
diabetes care in United Kingdom and Wales. The audit
collects information from both primary and secondary
care. Participation for the 2014–2015 NDA report was
around 4700 GP practices (57%) and 99 specialist services,
capturing information on 1.9 million people with
diabetes, with the national participation rate lower than in
previous years (70.7% national participation rate in the
audit year 2012–2013).10
Annual care processes recommended by the National
Institute for Health and Care Excellence (NICE) for all
people with diabetes aged 12 years and older encompass
blood tests (glycated haemoglobin (HbA1c), serum
creatinine, cholesterol), blood pressure, urine albumin,
foot surveillance, body mass index, and smoking history,
which is the responsibility of Diabetes Care Providers.10
Annual digital retinal screening, also recommended by
NICE, is the responsibility of National Health Service
(NHS) Diabetic Eye Screening. The percentage of people
with diabetes in United Kingdom and Wales receiving all
eight NICE recommended care processes by Diabetes
Care Providers in the audit year 2014-15 was 38.7%
for people with type 1 diabetes and 58.7% for people
with type 2 diabetes.10 Blood tests and blood pressure
checks are more reliably performed than other care
processes.10
Encouraging trends of improvement in blood pressure
control for people with type 1 and type 2 diabetes and
glucose control for type 1 diabetes were observed in the
NDA audit report 2013–2015.10 However, people aged
under 40 are much less likely to receive their care
processes and those under 65 with either type 1 or type 2
diabetes are much less likely to achieve recommended
treatment targets for HbA1c, blood pressure and
cholesterol compared with those aged 65 years and
older (Figure 2).10 There remain appreciable variations
in care process completion and treatment target
achievement between practices, between specialist
services and between CCGs and Local Health Boards
(LHBs).10
Furthermore, 75% of people newly diagnosed with
diabetes were offered structured education in United
Kingdom and Wales within 1 year of diagnosis in the
audit year 2014–2015, compared with only 10.3% in the
audit year 2010–2011. However, there is a large disparity
between structured education offers and attendances:
records of attending structured education have increased
only modestly to 5.3% in 2014–2015 compared with 3.4%
in 2012–2013.10
Table 1 Global prevalence estimates and healthcare expenditures 2015 and projection for 2040a
2015 2040
Global population
Total world population 7.3 billion 9.0 billion
Adult population (20–79 years) 4.72 billion 6.16 billion
Diabetes (20–79 years)
Global prevalence 8.8% (7.2–11.4%) 10.4% (8.5–13.5%)
Number of people with diabetes 415 million (340–536 million) 642 million (521–829 million)
Number of deaths due to diabetes 5 million
Healthcare expenditure due to diabetes (20–79 years)
Total health expenditure, R= 2b 2015 US dollars 673 billion 802 billion
aTable adapted with permission from International Diabetes Federation.2 bR= 2 estimate assumes healthcare expenditures for people with diabetes are on
average twofold higher than for people without diabetes.
Table 2 Estimates of diabetes prevalence in the United Kingdom
2016a
Country Number of people diagnosed with diabetes
in the adult population across the United Kingdom
in 2016 (QOF diagnosed)
United Kingdom 3 033 529
Northern Ireland 88 305
Scotland 280 023
Wales 188 644
Total 3 590 501
Abbreviation: QOF, Quality and Outcomes Framework 2015/16. aData
included with permission from Diabetes UK.4
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Summary: Diabetes is an escalating global health
challenge.
K Diabetes is an escalating global health challenge;
global diabetes prevalence has doubled since
1980.
K Type 2 diabetes, consequent upon complex pathophy-
siology but effectively driven by defective energy
homoeostasis and closely linked with obesity and
physical inactivity, accounts for the majority of people
with diabetes worldwide.
K Recent prevalence estimates of 2015 indicate that
around 9% of the adult population in United Kingdom
has diabetes (3.8 million people, of which 940 000 have
diabetes that is undiagnosed).
K Implementation of effective measures may help
prevent type 2 diabetes and improve management to
reduce diabetes-related complications and premature
deaths; obesity and overweight are the strongest risk
factors for type 2 diabetes.
K The National Diabetes Audit shows that those aged
under 65 with either type 1 or type 2 diabetes are
much less likely to achieve recommended treatment
targets for HbA1c, blood pressure, and cholesterol
compared with those aged 65 and older.
The diabetologists’ perspective: what an ophthalmologist
and other healthcare professionals need to know about
diabetes
Diabetes can cause major health problems related to
microvascular and macrovascular complications.
Diabetes was ranked the seventh leading cause of
disability worldwide in 2013, increasing by more than
two ranks compared with the same global evaluation of
leading causes of global years lived with disability in
1990.11 Chronic hyperglycaemia can seriously affect the
cardiovascular system, eyes, kidneys, and nerves, and in
almost all high-income countries, diabetes is a major
cause of cardiovascular disease, blindness, kidney failure
and lower-limb amputation.2
Report 2 from the National Diabetes Audit for
2012–2013 presents ﬁndings on diabetes complications
and mortality in United Kingdom and Wales.12 It shows
that people with diabetes are considerably more likely
than people without diabetes to be admitted to hospital
with angina, myocardial infarction, heart failure and
stroke, and are at far greater risk for a major amputation
and renal replacement therapy. The risk of a person with
diabetes being admitted to hospital for heart failure is
126% greater than among those without diabetes, while
the risk of major amputation (above the ankle) is 400%
higher.12 Furthermore, hospital length of stay is
considerably greater for people with diabetes than those
without,13,14 further compounding the economic and
healthcare system implications of the condition.
People diagnosed with diabetes are often active and
working, faced with the challenge of attending numerous
other medical appointments in cardiology,
ophthalmology, renal assessment, endocrinology, and
dietetics. Strain et al15 reported survey ﬁndings that
physicians had low expectations of their diabetic patients
in terms of attaining glycaemic control targets and
following advice on diet and physical activity. Moreover,
only a small proportion of diabetes patients believed
lifestyle changes were important and the majority failed
to comply.15 In terms of recall, people with diabetes had
at best a rudimentary understanding of the risk of
complications and the importance of good glycaemic
control. Only 25% of patients surveyed in this
multicountry evaluation reported being worried about
developing type 2 diabetes complications.15
Figure 1 Expected diabetes prevalence (diagnosed and undiagnosed) for England in 2015 by gender, ethnicity, and age group.5
A Public Health England (PHE). Diabetes Prevalence Model. Public Health England, September 2016. Contains public sector information
licensed under the Open Government Licence v3.0. The 2016 PHE diabetes prevalence model incorporates more up-to-date data sources
and population estimates than previously published diabetes prevalence models. The previous model published in 2012 underestimated
undiagnosed diabetes, suggesting that the overall prevalence estimates were probably low.
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People with diabetes are encouraged to help manage
their own disease through diet and exercise, blood
pressure and glucose monitoring and insulin
administration where indicated. The primary focus of
clinical diabetes care revolves around a multidisciplinary
team-based proactive approach to optimise risk factor
control and thus minimise the risk of diabetes-related
complications.
Early and sustained glycaemic control is important. Long-
term prospective studies, some involving follow-up over
several decades, underscore the beneﬁt of early and
sustained proactive glycaemic control in managing
diabetes. These assessments conclusively show that
reducing hyperglycaemia decreases the onset and
progression of microvascular complications, such as
retinopathy and nephropathy, in people with both
type 1 and type 2 diabetes.16–19
The Diabetes Control and Complications Trial (DCCT),
a randomised clinical trial with mean follow-up of 6.5
years, showed that intensive glycaemic control effectively
delays the onset and slows the progression of clinically
important diabetic retinopathy (DR) (change of at least
three steps from baseline that was maintained for at least
six months), including vision-threatening retinopathy,
nephropathy, and neuropathy in patients with insulin-
dependent diabetes.16 Intensive treatment reduced the
mean risk for development of retinopathy by 76% as
compared with conventional therapy and slowed the
progression of retinopathy by 54%.16
An observational follow-up study of the DCCT cohort
demonstrated a signiﬁcantly lower incidence of further
DR progression in the intensive treatment group (hazard
reduction 53–56%). The results indicate a durable
beneﬁcial effect, reinforcing the need for optimising
glycaemic control as early as possible in patients with
diabetes.20
The landmark UK Prospective Diabetes Study (UKPDS)
was a large, multicentre, randomised controlled trial that
compared the long-term effects of intensive blood glucose
control (aim of fasting plasma glucose ofo6 mmol/l) and
conventional dietary treatment on the risk of
microvascular and macrovascular complications in
people with type 2 diabetes. Long-term follow-up
results17 show that:
K Haemoglobin A1c was 53 mmol/mol (7.0%) in the
intensive group compared with 63 mmol/mol (7.9%)
in the conventional group over 10 years.
K Intensive blood glucose control substantially decreased
the risk of diabetic microvascular complications in type 2
diabetes.
K Compared with the conventional treatment group,
there was a 25% risk reduction (7–40, P= 0.0099) in the
intensive group in microvascular endpoints, including
the need for retinal photocoagulation.
Another study by the UKPDS Group, involving
hypertensive patients with type 2 diabetes and a median
follow-up of 8.4 years, showed that tight blood pressure
control (144/82 mmHg) achieved a clinically important
reduction in the risk of deaths related to diabetes,
Figure 2 Percentage of all people with diabetes in United Kingdom and Wales achieving all three treatment targets (HbA1c
≤ 58 mmol/mol (7.5%), blood pressure ≤ 140/80 mm Hg, and cholesterol o5 mmol/l) by diabetes type and age group, 2014–2015.10
National Diabetes Audit 2013–2014 and 2014–2015. Report 1: Care Processes and Treatment Targets. Published 28 January 2016 by the
Health and Social Care Information Centre (HSCIC), also known as NHS Digital. Contains public sector information licensed under the
Open Government Licence v3.0.
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complications related to diabetes, progression of DR, and
deterioration in visual acuity.21 After 9 years of follow-up,
the group assigned to tight blood pressure control had a
47% reduced risk (7–70%, P= 0.004) of deterioration in
visual acuity by 3 or more lines on the Early Treatment
Diabetic Retinopathy Study (ETDRS) chart.21
Ten-year non-interventional post-trial monitoring was
undertaken to determine whether improved glucose
control persisted and whether such therapy had a long-
term effect on macrovascular outcomes. Results revealed
a continued reduction in microvascular risk and emergent
risk reductions for myocardial infarction and death from
any cause in the patient group originally assigned to
receive intensive glucose-lowering therapy.18 Relative risk
reductions persisted at 10 years for microvascular disease
(24%, P= 0.001). This was despite an early loss of
between-group differences in HbA1c levels after the ﬁrst
year of post-trial monitoring.18
Multiple risk factor intervention for hyperglycaemia,
hypertension, and dyslipidaemia. Sustained beneﬁcial
effects on vascular complications from intensive proactive
multiple risk factor intervention was demonstrated in the
Steno-2 Study, which involved 160 patients with type 2
diabetes and persistent microalbuminuria.22 With a mean
follow-up of 7.8 years, results show that the relative risk
of developing kidney, eye, and nerve complications all
remained diminished by about 50% for the intensively-
treated group, treated with angiotensin-converting-
enzyme (ACE) inhibitors, statins, and glucose-lowering
drugs. The impact of such an approach is highlighted by
the fact that seven people in the conventional group
became blind in one eye, compared with only one person
in the group assigned to intensive therapy.22
Patients in the Steno-2 Study were subsequently
followed observationally for a mean of 5.5 years. The
intensive goal-directed multifactorial intervention group
demonstrated sustained beneﬁcial effects with regard to
vascular complications as well as all-cause and
cardiovascular complications.23
These data thus clearly illustrate the beneﬁt of a
proactive target driven multifactorial risk modiﬁcation
approach to optimising outcomes in people with type 2
diabetes.
Proactive clinical management of diabetes and co-morbidities,
emphasis on patient-centred care. Given the evidence of
beneﬁt and supported by both national and international
guidelines, a major focus for the care of people with type
2 diabetes is the achievement and maintenance of optimal
glucose control early within the natural history of the
condition.17,19,24 The clinical paradigm in managing
glucose control centres on individualisation of therapy as
there are many effective glucose-lowering agents to
choose from when tailoring individual
antihyperglycaemic treatment strategies for patients with
type 2 diabetes. A stepwise approach is typically adopted,
advancing from initial single drug therapy to dual
combination and triple drug combination therapy when
needed. Insulin therapy is considered a key component of
any combination regimen when hyperglycaemia is
severe.19
Treatment targets and strategies should be
individualised based on a patient-centred approach
(Table 3). This is reinforced in an updated joint position
statement from the American Diabetes Association and
the European Association for the Study of Diabetes.19
Personalisation of treatment is recommended, balancing
the beneﬁts and risks of glycaemic control, taking
account of the potential risk of hypoglycaemia and
other adverse effects and the patient’s age and health
status.19 Glycaemic control needs to be combined
with a comprehensive cardiovascular risk factor
reduction programme, to include smoking cessation
and the adoption of other healthy lifestyle habits,
blood pressure control, and lipid management.19
Personalised management plans for patients with
type 2 diabetes should therefore encompass glycaemic
control and effective blood pressure and lipid
management.
The initial management of type 2 diabetes involves
advice and education about the potential beneﬁts of
dietary modiﬁcation and lifestyle change, including
increased physical activity. An early objective is to
improve metabolic control through body weight
reduction and thereby potentially improve insulin
sensitivity.25 Many patients with diabetes however will
require pharmacological therapy over time and often
require escalation of treatment intensity. Only one in four
Table 3 Recommended approach to the management of hyperglycaemia in patients with type 2 diabetes: modulation of the
intensiveness of glucose lowering based on patient and disease features, a broad construct to guide clinical decision-makinga
Patient/disease features
⇐ HbA1c 53 mmol/mol (7.0%) ⇒
More stringent Less stringent
Risks potentially associated with hypoglycaemia and
other adverse drug effects
Low High
Disease duration Newly diagnosed Long-standing
Life expectancy Long Short
Important co-morbidities Absent Severe
Established vascular complications Absent Severe
Patient attitude and expected treatment efforts Highly motivated, adherent, excellent
self-care capacities
Less motivated, non-adherent, poor
self-care capacities
Resources and support system Readily available Limited
Abbreviation: HbA1c, glycated haemoglobin. aAdapted with permission from Inzucchi et al.19
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patients in the UKPDS trial maintained an HbA1c level
below 53 mmol/mol (7%) after 9 years without either oral
agents or exogenous insulin.25
Over one-third of patients taking oral glucose-lowering
medications report hypoglycaemic symptoms during the
past year, which limited treatment satisfaction and
therapy adherence.26,27 Fear of hypoglycaemia drives
poor therapy adherence and is one of the major barriers to
the achievement of good glucose control from both a
patient and healthcare professional perspective.26 In
addition, severe hypoglycaemia has been identiﬁed as an
independent risk factor in the aetiology of diabetes-
related co-morbidities,28 while hypoglycaemia along with
rapid improvements in glucose control contribute to an
increase in retinal complications and blindness.
Furthermore, severe hypoglycaemia and unawareness of
hypoglycaemia can have serious socioeconomic
implications, including suspension of a driving licence
and reduced work productivity.29–31
A variety of risk factors are related to hypoglycaemia
episodes, such as increasing age, longer duration of
diabetes (years since diagnosis) and complexity of insulin
regimen. Severe hypoglycaemia was found to be
prevalent in almost half of people with long-duration type
1 diabetes.32 A retrospective cohort study by Bruderer
et al33 found severe hypoglycaemia was recorded in 12
cases per 10 000 person-years in patients with type 2
diabetes in the United Kingdom who were newly treated
with anti-diabetic drugs.
Other factors such as treatment complexity, weight
gain, and socioeconomic factors can inﬂuence therapy
adherence and hence glucose control.26 Indeed, poor
treatment compliance, deﬁned as medication non-
compliance and/or non-attendance at medical
appointments, was found to be associated with all-cause
mortality in people with type 2 diabetes receiving insulin,
in a study of patient data extracted from United Kingdom
general practice records (n= 15 984).34 Clinic non-
attenders were more likely to be smokers, younger, have
higher HbA1c and have more prior primary care contacts
and greater morbidity.34
Patients decline participation in diabetes education
programmes for a variety of reasons, commonly for
logistical or ﬁnancial reasons or because there is no
perceived beneﬁt. Non-attendance because of health-
related shame and stigma of diabetes has been identiﬁed
as a reason for non-attendance at structured education
sessions in newly diagnosed type 2 diabetes patients.35
Alternative and innovative methods for delivering
diabetes education beyond the conventional group format
may encourage greater participation and individual
empowerment.
Early intervention required to limit risk and progression of
complications. Successful diabetes care requires a
comprehensive proactive approach. A major objective of
effective partnership between local primary care
physicians and diabetology services is to maintain
patients’ quality of life and reduce treatment-related
morbidity, such as hypoglycaemia. Patient engagement is
central, encouraging individuals to know and own their
data so as to maximise and maintain commitment and
outcomes. Early and effective glycaemic control reduces
microvascular risks and helps prevent later
macrovascular complications.36 People with diabetes
often have busy lifestyles and any initiative to reduce the
amount of time required for hospital attendance or visits
to the doctor’s ofﬁce is beneﬁcial and may contribute to
lowering overall healthcare costs.
Summary: What an ophthalmologist and other healthcare
professionals need to know about diabetes.
K The primary focus of clinical diabetes care revolves
around a multidisciplinary team-based proactive
approach to optimise risk factor control and
thus minimise the risk of diabetes-related
complications.
K In people with diabetes, early optimal glycaemic
control reduces the long-term risk of both microvas-
cular and macrovascular complications.
K Fear of hypoglycaemia drives poor therapy adherence
and is one of the major barriers to the achievement of
good glucose control.
K Glycaemic control needs to be combined with a
comprehensive cardiovascular risk factor reduction
programme, to include smoking cessation and adop-
tion of other healthy lifestyle habits, blood pressure
control, and lipid management.
Summary: National Institute for Health and Care
Excellence (NICE) priorities for the management of type 2
diabetes in adults.24
K Structured education: Guidelines for managing adults
with type 2 diabetes from NICE stress provision of
structured education as an integral part of diabetes care.
K Dietary advice and lifestyle modiﬁcation: Dietary advice
should form part of a personalised diabetes manage-
ment plan that includes other aspects of lifestyle
modiﬁcation, such as increasing physical activity and
weight loss.
K Management of blood glucose: Adults should be actively
encouraged to achieve their individual HbA1c target
and maintain it unless adverse effects, or their efforts
to achieve their target, impair their quality of life. If
HbA1c levels are not adequately controlled by a single
drug and rise to 58 mmol/mol (7.5%) or higher,
clinicians are advised to reinforce dietary advice,
lifestyle and adherence to drug treatment, support the
person to aim for an HbA1c level of 53 mmol/mol
(7.0%) and intensify drug treatment.
K Hypertension: Antihypertensive medications should
be added if lifestyle advice does not reduce blood
pressure to below 140/80mmHg (below 130/80mmHg
if there is kidney, eye or cerebrovascular damage) and
antihypertensive treatment intensiﬁed if necessary until
the blood pressure is consistently below 140/80mmHg
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(below 130/80mmHg if there is kidney, eye or
cerebrovascular damage).
K Insulin therapy: Insulin therapy for adults with type 2
diabetes should be considered if blood glucose levels
are inadequately controlled despite dual therapy with
metformin plus another oral anti-diabetic drug (if the
person is markedly hyperglycaemic and prefers to
start insulin rather than adding another drug), or
where oral anti-diabetic drugs are contraindicated or
not tolerated.
Diabetic retinopathy screening in the United Kingdom:
high coverage achieved, challenges and opportunities
ahead
Screening for sight-threatening DR and maculopathy
aims to detect diabetic eye disease at an appropriate stage
in the disease process when treatment has a higher
likelihood of success. Broad population coverage is
essential and all people should be screened promptly and
regularly after diagnosis of diabetes.
The rate of detection of referable DR is higher in those
who are not screened promptly after diagnosis of type 2
diabetes, illustrating the need for strategies to increase
uptake in those with a poor attendance record,37 for
example, use of easy-to-read information and translated
letters.38 Zoega et al39 described the relationship between
non-attendance for diabetic eye disease screening and
blind registration (VA o0.3) in a small sample of
diabetes patients in Iceland, observing a signiﬁcant
relationship between screening compliance and visual
outcome. Those people aged 18–34 years are least likely
to attend promptly for screening after registration, with
a higher risk of referable DR being present at ﬁrst
screen.40
Success in tackling vision impairment and blindness from DR
in people of working age. The NHS Diabetic Eye Screening
Programme involves a systematic approach designed to
capture all people with diabetes for photographic
screening once each year. People newly diagnosed with
diabetes are invited annually for digital retinal
photography screening and images are subjected to
feature-based grading (Figure 3 outlines the retinal
screening grading pathway).41 Assessments demonstrate
the effectiveness of screening for DR by 2-ﬁeld mydriatic
digital photography, with good levels of sensitivity
(87.8%) and speciﬁcity (86.1%) that compare well with
seven ﬁeld stereophotography and an ophthalmologist’s
examination using slit lamp biomicroscopy.42,43 Those
found to have potentially sight-threatening DR are
referred to surveillance clinics or the NHS Hospital Eye
Service.
The national screening programme has progressively
evolved to achieve high population coverage in excess of
80% in United Kingdom. In 2014–2015, there were 83 local
screening programmes involving both NHS and private
providers in United Kingdom. That year, 2.5 million people
with known diabetes were offered screening appointments
and 2.1 million people were screened (84%). In the last
10 years, the epidemic of diabetes has seen an increase of
120 000 cases every 12 months. Of the 1.89 million people
screened in United Kingdom in 2012–2013, 5.6% were
graded background DR with maculopathy, 0.61% pre-
proliferative DR without maculopathy, 0.59% pre-
proliferative DR with maculopathy, 0.32% proliferative DR
without maculopathy and 0.42% proliferative DR with
maculopathy.
Similarly, the national Diabetic Retinopathy
Screening Programme in Scotland screened 78.7%
(201 299 individuals) of eligible people in 2014–2015,
just below the Scottish national target of 80%.44 The
national trend for 2014 was 8 916 new diabetes patients
becoming eligible for screening across Scotland through
12 months. The annual percentage of referrals to
ophthalmology on account of retinopathy is around
3.5%.44
Many people with diabetes have been prevented from
losing vision through early detection and timely
intervention. Liew et al45 reported that in persons aged
between 16 and 64 years inclusive in 2009–2010, diabetic
retinopathy/maculopathy was no longer the leading
cause of certiﬁable blindness in United Kingdom and
Wales, accounting for 14.4% of blindness certiﬁcations
compared with 17.7% in 1999–2000. The underlying
reasons for this change are thought to include the
introduction of nationwide DR screening programmes in
United Kingdom and Wales and improvements in
glycaemic control.
Although DR is no longer the leading cause of severe
sight impairment among working age adults in the
United Kingdom, it remains a major cause of registrable
blindness, second to hereditary retinal disorders.
Prevalence ﬁgures from the National Ophthalmology
Database show that, of a large cohort of diabetes patients
assessed for DR in the UK Hospital Eye Service, almost
Figure 3 Retinal screening grading pathway, NHS England.
Public Health England.41 Public health functions to be exercised
by NHS England. Service speciﬁcation No 22. NHS Diabetic Eye
Screening Programme. Department of Health, NHS England,
November 2013. Contains public sector information licensed
under the Open Government Licence v3.0. Abbreviations: M0, no
maculopathy; M1, maculopathy; R0, no retinopathy; R1, back-
ground retinopathy; R2, pre-proliferative retinopathy; R3a, active
proliferative retinopathy; R3s, stable proliferative retinopathy.
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10% of eyes have centre-involving diabetic macular
oedema (DMO) and around 20% have proliferative
disease.46 Vitrectomy surgery for the late complications of
proliferative DR continues to be required for some
patients.47
New challenges and opportunities to improve screening
performance and referral reﬁnement
Risk stratiﬁcation and personalised screening
intervals. Duration of diabetes is independently
associated with microvascular events in type 2 diabetes,
an effect that is greatest at younger age.48 The more
prolonged the diabetes, the higher the prevalence of DR.
However, the duration of diabetes is generally
inconsistently documented and collated in clinical
practice.
Better glycaemic control and to a lesser extent blood
pressure control may be beneﬁcial in reducing the
incidence of proliferative DR and increasing the odds of
improvement of DR.49 The 25-year cumulative rate of
progression of DR was 83% and the rate of progression to
proliferative DR was 42% in the Wisconsin Epidemiologic
Study of Diabetic Retinopathy.49 Less severe DR, male
gender, higher HbA1c, an increase in HbA1c level and an
increase in diastolic blood pressure from the baseline to
the 4-year follow-up increased the likelihood of
progression of DR.49
The risk of progression of DR is signiﬁcantly higher for
those with background DR in both eyes than for those with
background retinopathy in only one eye or in neither eye.50
The cumulative 4-year risk of development of referable DR
was 1 in 3 for those with bilateral background DR, compared
with less than 1 in 10 and 1 in 20 for those with only one eye
or neither eye affected, respectively. With respect to the
ETDRS severity scale, mild or non-proliferative DR or
background DR (R1) identiﬁes a minimum of at least the
presence of one microaneurysm and/or retinal haemorrhage,
equivalent to ETDRS levels 20–35; R1b deﬁnes the presence
of these features in both eyes.50,51
Two risk stratiﬁcation models, one incorporating
results from a single screening episode plus clinical
information (HbA1c in the twelve months prior to
screening and duration of diabetes) and another the
results from two screening episodes alone, have been
developed and validated.52,53 These models discriminate
well between those with very low and with high risk of
progression to sight-threatening DR, which includes the
risk of developing maculopathy as well as the risk of
development of pre-proliferative DR or proliferative DR.
Experience from the Diabetic Eye Screening Programme
has helped develop risk stratiﬁcation showing the risk for
sight-threatening DR after 6 years is 1.7% compared with
a risk for any retinopathy of 39%.52
The increasing numbers of people with diabetes presents
challenges in maintaining a yearly screening service for all
eligible diabetes patients. Following consultation, the UK
National Screening Committee has recommended that in
people at low risk of sight loss, the interval between screening
tests should be changed from one year to two years.
Extending the screening interval in selected low-risk cases is
expected to reduce the number of unnecessary referrals to
specialist eye services. Further outstanding questions need to
be addressed however before implementation of these policy
proposals. While observational studies in low-risk patients
show little difference in clinical outcomes between 1 and
2-year screening intervals, Taylor-Phillips et al54 have argued
there is insufﬁcient evidence currently to support
recommendations to extend the screening interval beyond
one year.
Using optical coherence tomography as a second-line screening
tool for those who are screen positive for maculopathy on
2-dimensional photographic markers: helping address
over-referrals. The English Diabetic Eye Screening
Programme has introduced surveillance into the
approved service pathway standard. Cases that are
classiﬁed as background DR with maculopathy (R1M1) in
one or both eyes are also classiﬁed as having sight-
threatening DR but are sometimes offered interim review
appointments in surveillance clinics, depending on
severity and circumstances.
Spectral domain optical coherence tomography
(SD-OCT) imaging is a useful adjunct to colour fundus
photography in screening for referable diabetic
maculopathy.55 A prospective audit was performed of
patients referred from the diabetic eye screening
programme with mild to moderate non-proliferative
DR (R1) and maculopathy in either eye attending an
OCT-guided surveillance clinic. Results showed such
cases had a 42.1% chance of having no DMO on SD-OCT
imaging when graded by a retina specialist.55
In the Gloucestershire Diabetic Eye Screening
Programme, the service pathway includes a surveillance
clinic for certain cases that are classiﬁed on screening
episode by digital photography as background DR and
maculopathy in one or both eyes. Spectral domain OCT is
utilised to grade and identify macular pathology. An
audit of a consecutive case series (n= 724) referred from
the screening programme with background DR and
maculopathy found only 20% needed to be referred to the
NHS Hospital Eye Service for further review by an
ophthalmologist, avoiding unnecessary hospital referral
in 80% of screen-positive maculopathy cases (Table 4).
Optical coherence tomography criteria and deﬁnitions
used to grade scans as positive for referable diabetic
maculopathy and borderline criteria are detailed in
Table 5.
Table 4 Referral decisions in a consecutive case series of
diabetes patients following OCT-guided assessment in Glouces-
tershire Diabetic Eye Screening surveillance clinic (n= 724)
Referral outcome Number of
people
Percentage
OCT/photographic clinic 426 59%
Referred to Ophthalmology Eye
Clinic
146 20%
Annual screen 122 17%
Rebooked 21 3%
Deceased 9 1%
Abbreviation: OCT, optical coherence tomography.
Guideline
S8
Eye
Automated image analysis software systems to augment
manual graders. Manual grading is labour and capital
intensive and requires trained, qualiﬁed graders.
Systematic telemedicine digital retinal screening
programmes have been introduced in a number
of countries aiming to reach all people with
diabetes.
Automated retinal image analysis systems may
complement pure human grading, for example as an initial
ﬁlter in routine screening prior to primary human grading
or as a quality assurance tool, with manual grading as the
reference standard.56 Studies are ongoing comparing the
performance and economic costs of manual versus
automated DR image assessment. Preliminary
observational study results conﬁrm that automated image
assessment software systems provide acceptable sensitivity
for referable retinopathy when compared with human
graders, with sufﬁcient speciﬁcity to make them cost-
effective alternatives to manual grading alone.56
Summary: Retinal screening in the United Kingdom:
progress and challenges.
K Although DR is no longer the leading cause of severe
sight impairment among working age adults in the
United Kingdom, it remains a major cause of
registrable blindness.
K Strategies are needed to increase uptake in those with
a poor attendance record.
K Risk stratiﬁcation using one screening episode plus
clinical risk factors (HbA1c in the twelve months prior
to screening and duration of diabetes) or the results from
two screening episodes alone can be used to identify low-
risk groups who may require less frequent screening.
K Using OCT as a second-line screening tool in a screening
surveillance clinic for those who are screen positive for
maculopathy on photographic imaging may help reduce
unnecessary referrals to the NHS Hospital Eye Service.
K Automated retinal image analysis systems may
complement manual grading, providing an initial
ﬁlter in routine screening prior to primary human
grading or as a quality assurance tool.
Patient experience and adherence with intravitreal
injection therapy for visual impairment due to DMO:
results of a qualitative research study
DMO is a common complication of DR. The risk for
developing DMO is associated with duration of diabetes
and severity of DR. Estimates of the DMO prevalence rate
range from around 1 to 12% of all people with diabetes.57
A study estimated 7% of people with diabetes in United
Kingdom had DMO, and of these, more than one-third
(39%) had clinically signiﬁcant macular oedema with
visual impairment (visual acuity o6/6 in at least one
eye).58
Therapeutic options for the management of DMO
include laser photocoagulation, vitrectomy, corticosteroid
therapy, and intravitreal anti-vascular endothelial growth
factor (anti-VEGF) treatment. Macular laser
photocoagulation has been the historic mainstay
treatment for DMO over the past several decades.
Intravitreal corticosteroid therapy has shown efﬁcacy in
improving VA in patients with DMO and may play a role
in the treatment of adult pseudophakic DMO patients
who fail to respond sufﬁciently to prior non-corticosteroid
therapy, or are considered unsuitable for non-
corticosteroid therapy.59–61 Anti-VEGF therapy,
associated with substantially improved visual and
anatomic outcomes compared with laser
photocoagulation in patients with DMO,62 is considered
the standard of care for initial management of eyes with
visual impairment from central-involved DMO.59,62,63
Focal laser is an option for cases of non centre-involving
DMO.64
Anecdotal evidence suggests that treatment adherence
for some patients with intravitreal injection therapy for
DMO is not optimal. A qualitative research study,
commissioned by Bayer, was undertaken to elucidate
patient experience and treatment adherence patterns
amongst a diverse range of patients with DMO. The
research programme also assessed patient compliance
from the perspective of healthcare professionals and
explored clinical and practical solutions that may help
improve compliance, including clinic attendance. See
Supplementary Information—Patient Experience and
Adherence in DMO.
Individual in-depth interviews were conducted with 18
DMO patients being treated with licensed anti-VEGF
therapy within the NHS Hospital Eye Service. Ten of 18
Table 5 Criteria utilising spectral domain optical coherence tomography (OCT) as an adjunct to colour fundus photography in diabetic
eye screening surveillance clinic
OCT positive criteria:
The presence of subretinal ﬂuid or diffuse retinal thickening or intraretinal cystoid spaces associated with a change in the internal
limiting membrane (ILM) or foveal contour
The presence of intraretinal cystoid spaces and associated with:
A drop in visual acuity (VA) to ≤ 6/12; or
With a large area of greater than 1 disc area of ﬂuid the edge of which is within 1 disc diameter of the central fovea
Retinal thickness in the foveal central subﬁeld ≥ 300 μm
OCT borderline criteria:
The presence of intraretinal cystoid spaces, or subretinal ﬂuid, without any change in the ILM contour, and foveal central subﬁeld
≤ 300 μm in the central 1 mm macular subﬁeld
With VA ≥ 6/9
Without a large area of leakage of greater than 1 disc area the edge of which is within 1 disc diameter of the central fovea
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patients were regarded as non-compliant with treatment,
deﬁned as any missed appointment. The patient sample,
drawn from ten different clinical centres in United
Kingdom, Scotland, and Wales, was broadly mixed by
age (range 35–65) and socioeconomic grouping. The
majority (15/18) were men. Ten healthcare professionals
(six consultant medical retina specialists, one advanced
nurse practitioner and three nurse practitioners) from UK
ophthalmology centres and all having experience in the
management of both compliant and non-compliant DMO
patients were also interviewed. Extracts are reproduced in
Table 6.
Perspectives of the healthcare professional: proactive support
may help improve health outcomes. Many patients do not
immediately associate sight-threatening DMO with
diabetes and time is required to explain the implications
of their diabetic eye disease. People with diabetes need to
be informed of the risks to their sight early on in their care
pathway. Although it cannot be achieved in all patient
groups, healthcare professionals should counsel patients
on diabetes control, encourage them to understand the
threat of vision loss from DMO and to manage their
diabetes. Ethnic, cultural and language barriers
however can make this approach difﬁcult to achieve in
all cases.
The thought of intravitreal injections and an
intensive appointment schedule can be stressful for
patients. The burden of treatment for bilateral DMO in
particular can present challenges for patients who are
coping with other diabetes-related co-morbidities.
Anxiety often can persist throughout treatment and
may be addressed with appropriate educational
interventions.
Wilful or deliberate non-compliance was generally
found to be rare. According to healthcare professionals
interviewed, education about diabetes control could be
better addressed, individually tailored to take account of
ethnicity, age, and social needs. The introduction of a
DSN in a dedicated pathway for patients with DMO
may help to improve outcomes,65 generating positive
patient experience and awareness and potentially
improve individual motivation towards participation in
structured education programmes and for attaining and
maintaining good blood glucose and blood pressure
targets.
Patients’ perspectives. At the time of a diagnosis of DMO,
patients typically experience worry, concern, and fear. For
patients, fear of intravitreal injections and uncertainty
over a proposed treatment plan without a determinate
end often overshadow all other concerns. Explanations at
the time of consultation about the importance of regular
retreatment to avoid deterioration of vision and the
association between diabetes, glycaemic control, and sight
loss may be obscured by needle phobia or general
treatment anxiety.
A lack of awareness of DMO, the risk of visual
impairment if left unchecked, and the link to chronic
diabetes was common. This dilutes the important
communication that is required between doctor and
patient in a DMO clinic. Patients require access to up-to-
date educational materials about DMO, including useful
signposting to authoritative sources, both before and at
the point of diagnosis, to reinforce and encourage better
diabetic control. Nine in ten adults report going online
every day, reﬂecting the fact that internet use is an
integral part of many people’s daily lives.66 Multichannel
Table 6 Revealing extracts, see Supplementary Information—Patient Experience and Adherence in DMO
K Perspectives, in the words of consultant retina specialists
J 'I always look to see what kind of diabetic patient they are. Their treatment history, how their HbA1c is controlled and what they
do for themselves to manage their diabetes. It will tell me a lot about their diabetic macular oedema.'
— Consultant Retina Specialist
J 'We really need more ability to intervene with diabetes patients to encourage behaviour change, but we just don’t have the time
or resources or links to other services. All I can really do is tell them what they should be doing and hope they listen.'
— Consultant Retina Specialist
K Perspectives, in the words of DMO patients
J 'The best thing I ever did was the Dose Adjustment For Normal Eating (DAFNE) course. I learnt about diet and exercise and how
to manage my insulin and my diabetes.'
— Compliant DMO patient
J 'I was really upset when I got the diagnosis (of diabetes), I didn’t want to have a disease and certainly not one that would ruin
my life.'
— Non-compliant DMO patient
K Experience of the DMO journey, in the words of DMO patients
J 'The reaction in my eyes was caused by a dramatic drop in my glucose levels. I was told it may have dropped too quickly and
affected the vessels in my eyes.'
— Compliant patient
J 'I was in bits when they told me I had DMO. It is bad enough being diabetic and now I could go blind! I felt like my life had
ended and then they tell me I needed to have an injection in my eye and that was terrifying beyond belief.'
— Non-compliant DMO patient
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access to educational materials increases awareness and
involvement and may motivate the patient with regard
to DMO treatment compliance and prioritisation of
lifestyle modiﬁcation to better control modiﬁable risk
factors.
Three psychological proﬁles were identiﬁed in the
research study that characterise the main differences
amongst people with diabetic macular oedema attending
DMO clinics: ‘evangelists’, the ‘generally sensible’ and ‘those
not always well behaved’ (Figure 4). The evangelical patient
takes a keen interest in the condition, focused on adjusting
lifestyle to help achieve better management of diabetes.
They are disciplined and very compliant. The generally
sensible proﬁle probably covers the majority of patients,
who listen, are interested, have good intentions and achieve
good compliance most of the time, with occasional lapses in
clinic attendance. Then there are patients who are not
always well behaved, embracing a range of behaviours: past
non-compliance, those in denial of their condition, or
preoccupied with ‘chaotic’ and busy lifestyles.
Attitudes towards DMO treatment adherence were
found to mirror patients’ views and behaviours in relation
to the management and care of their own diabetes. Fear of
visual impairment from DMO added a further patient
proﬁle: the ‘transformed’. These are patients who
previously have not always been well behaved, but
whose diabetic compliance has been markedly improved
(transformed) by the diagnosis of DMO and resulting fear
of blindness.
Experience of the DMO journey. Patients appreciate the
explanation and reassurance provided by healthcare
professionals at the time of commencing DMO treatment.
However, they are aware of time and resource pressures
within NHS hospital clinics. A perception of busy clinics
can make patients reluctant to ask too many questions or
take up too much time with clinicians. Not all patients
want information upfront about DMO, preferring a
stepwise approach one appointment at a time. Others
prefer to absorb as much information as possible at the
outset.
Compliant patients are more likely to understand the
need for good diabetic control and are encouraged by
threat or symptoms of sight loss. For such patients,
explanation and counselling by healthcare professionals
acts to support or reinforce compliance.
Not all patients with DMO receiving intravitreal anti-
VEGF therapy are aware of the nature of the treatment
regimen or understand the importance of the treatment
intervals involved. Non-compliant patients are often least
aware of the need to have repeat injections at prescribed
intervals. This could be addressed by providing newly
diagnosed DMO patients with good website links or
patient information leaﬂets providing useful guidance
about the course of treatment involved and about how
treatment frequency typically peaks in the ﬁrst year and
diminishes over subsequent years.67
Mobile text messaging may encourage improved compliance
with scheduled clinic visits. There were 91.5 million
United Kingdom mobile subscriptions at the end of
2015.66 Seventy-one per cent of all UK adults own a
smartphone, up from 66% in 2015.66 Ofcom research
shows that 66% of adults claimed to access data services
on a mobile phone in 2016, with a signiﬁcant increase
since 2015 noted for users aged 55 and older (20% of
respondents aged 55+ in 2016 compared with 11% in
2015).66
Hence, text message reminders could be more widely
utilised to reinforce and encourage good patient
attendance for scheduled appointments and minimise
‘did not attend’ rates, particularly for those who might be
reluctant to turn up. A systematic literature review of
studies on mobile telephone message reminders in
healthcare services found 70% of the studies showed
improved outcomes.68 Mobile phone text messaging
reminders have been shown to increase attendance at
healthcare appointments when compared to no reminders
or postal reminders.69
Message content and timing in relation to an
appointment should be carefully considered. The ideal
may be a letter some weeks beforehand, so that time off
work can be booked, followed by a simple text message
reminder a couple of days prior to the appointment.
Summary: Qualitative research study exploring patient
treatment adherence patterns with intravitreal injection
therapy for DMO.
K People with diabetes need to be informed of the risks
to their sight early on in the management of their
diabetes care.
K Attitudes towards DMO treatment adherence appear
to mirror patients’ views and health behaviours in
relation to the management and care of their own
diabetes.
Figure 4 Characteristic psychological proﬁles of diabetes
patients, covering attitudes to diabetes and its treatment. Three
distinct types of diabetes patient were identiﬁed, which
match DMO patient proﬁles, with the threat of blindness or
experience of visual impairment creating an additional proﬁle
—‘Transformed’.
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Figure 5 Type 1 and type 2 diabetes: diabetes specialist eye nurse care pathway, University Hospitals of Leicester.
Abbreviations: BMI, body mass index; CK, creatine kinase; DR, diabetic retinopathy; FFA, fundus ﬂuorescein angiography; F/U,
follow-up; HbA1c, haemoglobin A1c; LDH, lactate dehydrogenase; OHAs, ocular hypertensive agents; TFTs, thyroid function tests;
U&E, urea and electrolytes; VA, visual acuity. Reproduced with permission from UHL ophthalmology department.
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K Patients require access to up-to-date educational
materials about DMO and the importance of adher-
ence to treatment schedules, both before and at the
point of diagnosis.
K Text message reminders could be more widely utilised
to reinforce and encourage good patient attendance
for scheduled appointments and minimise ‘did not
attend’ rates.
Expanding the role of the diabetes specialist nurse in
diabetic eye clinics
Practice interventions by a DSN promotes proactive
modiﬁcation of lifestyle behaviours and may improve
glycaemic status and overall metabolic control. A
randomised study in Sweden, involving data collection in
2010 and 2011, found nurse-led intervention focused on
patient-centred self-management support lowered HbA1c
among patients with type 2 diabetes at 12 months’ follow-
up.70 Glycated haemoglobin level signiﬁcantly decreased
from baseline in patient groups randomised to group
intervention and individual intervention by 5 and
4 mmol/mol, respectively. An external control group
recruited from another county council showed increased
HbA1c from baseline.
An earlier published report from practitioners at
University of Hospitals of Leicester NHS Trust showed
positive results in an audit of a service pathway involving
a diabetes specialist eye nurse working in both the
diabetes and ophthalmology clinics (Figure 5 shows the
care pathway and protocol).65 Khan et al65 reported
improved glycaemic control and reductions in mean
cholesterol levels at 12 months’ follow-up in a cohort of
100 people with diabetic eye disease. For the full audited
cohort, mean HbA1c level reduced from 71 mmol/mol
(8.67%) at baseline to 60 mmol/mol (7.64%) at 12 months’
follow-up examination.
A majority of diabetes patients with severe DMO
(78–82% of 52 patients) failed to achieve a glycaemic
control target of ≤ 48 mmol/mol (6.5%), in a retrospective
audit of results from a regional hospital eye clinic in
United Kingdom with conventional treatment without
direct DSN intervention.71 The data suggest there is room
for improvement in the management of diabetes patients
being treated for DMO.
Exploring the role of the DSN in diabetic ophthalmic
practice. The DSN role exists to educate and support
people living with diabetes and their families at all stages
of their lives, motivating people to self-manage their
diabetes as effectively as possible. The DSN provides
expertise as part of dedicated diabetes teams and assists
other healthcare professionals in the care they provide.
Considered the patient’s advocate, the DSN can act as a
valuable bridge between healthcare professionals and
services in primary, secondary and integrated care.
Nurse-led structured education programmes encourage
people to manage modiﬁable risk factors for onset and
progression of diabetic eye disease, by optimising control
of blood glucose levels, blood pressure and lipid
management.
Careful instructions are provided on when and how to
self-test blood glucose and what to do with the results.
Smoking cessation is stressed, as is the importance of
regular eye examination for early identiﬁcation and
initiation of care for patients with retinopathy. The main
modiﬁable risk factors for type 2 diabetes are overweight
and obesity, insufﬁcient physical activity and unhealthy
dietary practices.1 Results of a parallel-group, randomised
controlled trial at 56 primary care practices in Central and
South United Kingdom found that an internet-based
intervention with brief practice nurse support helped
people maintain clinically important weight reductions
over 12 months.72
Patients with diabetes require access to concise written
material and online educational resources. Often there
appears to be a lack of emphasis at the time of diabetes
diagnosis on the relationship between managing known
risk factors and development of diabetic eye disease.
Diabetes patients should understand the need for good
glycaemic control, as progression of eye disease is
associated with the severity and duration of
hyperglycaemia, and for effective treatment of
hypertension.73–75
Stratton et al76 found that development of retinopathy
in type 2 diabetes over 6 years from diagnosis was
strongly associated with baseline glycaemia, glycaemic
exposure over 6 years and higher blood pressure.
Progression of existing retinopathy was associated with
older age, male gender and hyperglycaemia. Intensive
treatment of both hyperglycaemia and hypertension is
advisable to help minimise the incidence of diabetes
complications.75
Vision impairment negatively impacts quality of life
and may restrict independence and mobility. Even mild
impairment (near-normal vision) has a tangible inﬂuence
on quality of life. Cumberland et al77 reported that, in a
gradient of increasing severity, all-cause impaired visual
function was associated with adverse social outcomes and
impaired general and mental health. Vision-reliant tasks
are required for good chronic disease management,
including self-care (eg, foot checks in diabetes) and
getting to and from clinic visits.78 Vision loss also may
complicate the management of other conditions by
creating difﬁculties in medication adherence and
management, for example, administering insulin or
eye drops.
The DSN can ensure baseline investigations for risk
factors are completed at time of initial assessment for
patients with DMO, refer patients at high risk of visual
loss to a diabetologist (eg, poorly controlled hypertension,
raised lipid parameters, microalbuminuria) and
encourage good follow-up attendance for patients at risk
of visual deterioration.
Summary: Expanding the role of the diabetes specialist
nurse in dedicated eye clinics for patients with diabetic
macular oedema.
K Often there appears to be a lack of emphasis at the
time of diabetes diagnosis on the relationship between
managing known risk factors and development of
diabetic eye disease.
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K Practice interventions by a diabetes specialist nurse
(DSN) promotes proactive modiﬁcation of lifestyle
behaviours and may improve glycaemic status and
overall metabolic control.
K Wherever feasible, the introduction of a DSN in a
dedicated DMO eye clinic may help to improve care
outcomes.
K The DSN can ensure baseline investigations for risk
factors are completed at time of initial assessment
following referral, direct patients at high risk of visual
loss to a diabetologist and encourage good follow-up
clinic attendance and treatment adherence.
Practice principles and clinical considerations
In diabetes management, commitment of patients
can deteriorate over time. People generally are more
willing to consider behavioural change at the time
of diabetes diagnosis. But enthusiasm typically wanes,
with condition fatigue emerging with therapy escalation.
Poor glucose control is often explained by clinical
inertia, which limits or delays intensiﬁcation of
treatment when needed in the management of
diabetes.79
Diabetic retinopathy and DMO are the two major
retinal complications that account for most diabetes-
related vision loss.80 Left unchecked, approximately half
of people with DMO at baseline lose 2 or more lines of
visual acuity within 2 years.74 Hyperglycaemia,
hypertension and dyslipidaemia are risk factors for
both the development and progression of DR/DMO
and there is substantial evidence that control over
metabolic factors can effectively prevent development
and progression of potentially blinding diabetic eye
disease.74
For optimal clinical care of patients with visual
impairment due to DMO, several practice-based
principles merit consideration in NHS ophthalmic service
provision and care pathway redesign.
Practice-based principles for optimal clinical care
Principle 1. Foster closer working relationships
between diabetes management, general practitioners,
and ophthalmology specialties. Closer clinical
collaboration between diabetology, primary care, and
ophthalmology services may enhance patient
experience.
The ophthalmologist should establish who is taking
care of the individual patient’s diabetes and, as
emphasised in clinical guidelines for DR from the Royal
College of Ophthalmologists,64 develop strong links with
local primary care and diabetology services to ensure that
patients have effective integrated care plans for the
management of their condition.64 The aim is to achieve
closer working relationships so that patients with DMO or
advanced or progressive retinopathy are appropriately
managed from both the perspective of ophthalmology
and diabetes management.
Much of the clinical focus in diabetes management
is to limit the burden of diabetes-related complications.
A structured approach to education concerning
health behaviours and health promotion is beneﬁcial
and higher uptake should be encouraged. Multiple risk
factor intervention is required to reduce disease
burden and improve clinical outcomes, generating
value at the individual, clinical and health system
level.
In tailoring diabetes management to individual patients
who are being treated for DMO, the diabetologist would
beneﬁt from knowing the patient’s degree of sight loss,
frequency of current treatment and expected prognosis.
The diabetes management team should be aware of the
main prognostic factors for increased risk of development
and progression of sight-threatening DMO. This would
enable the diabetes care team to identify high-risk patients
at an early stage, for example, obesity, sleep apnoea, and
elevated risk of progression of DR.81
Principle 2. Consider the beneﬁts of establishing a
dedicated clinic service for the management and follow-
up of patients with DMO. Consider streamlining the
pathway of diagnosis and treatment of DMO, with an
emphasis on improving education and awareness,
multidisciplinary working, expanding the role of the DSN
in dedicated DMO clinics, and ensuring communication/
liaison with colleagues beyond ophthalmology is effective
and sufﬁcient.
More time during consultation is needed for patients, to
educate them about their diagnosis, treatment, outcomes,
and diabetes control. Dedicated service provision for
DMO would also facilitate integration of a DSN-led
review service thus enhancing efﬁciency of diabetes care.
The English Diabetic Retinopathy Screening Programme
and guidance on retinal screening from the Royal College
of Ophthalmologists have for a long time recommended
dedicated assessment clinics in the NHS Hospital Eye
Service for people with diabetic eye disease referred for
ophthalmologist review.
Dedicated clinics for patients with diabetic eye disease
would help promote:
K The value of early detection and intervention;
K Delivery of sustained education and health promotion;
K Multidisciplinary working and engagement with
other healthcare professionals working with diabetes
patients;
K Flexible service provision and clinics for greater
patient engagement; and
K Identiﬁcation of high-risk patients.
Practice varies across the United Kingdom with
regard to injection treatment clinics for DMO. While
many centres choose to treat all eligible patients
with retinal disease during a combined medical retina
injection treatment service for example, other clinical
centres prefer to maintain separate assessment and
injection clinics for patients with DMO. Protocols
for assessment and monitoring, as well as the
recommended treatment posology with intravitreal
anti-VEGF therapy, vary for different retinal disease
entities.
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Principle 3. Explore aspirations and opportunities to
expand the role of the DSN in the hospital eye clinic, with
the nurse specialist acting as the main hub between
ophthalmology, endocrinology, diabetology, and primary
care services/support. Specialist input from a diabetes
expert is required when dealing with DMO patients
coping with established diabetes-related complications
and who may be at risk of mild or moderate vision
impairment and of other later macrovascular
complications because of poor metabolic control. Diabetes
experts urge ophthalmologists to make better use of the
specialist diabetes services available. Commissioners
investing in local services should also support expansion
and strengthen DSN recruitment so they may logistically
be in a position to provide further coverage within
hospital eye departments.
Principle 4. Tailor clinical practice and follow-up
initiatives to improve treatment adherence in DMO. A
wide range of appointment times should be available for
patients with diabetes. Afternoon, evening or weekend
appointments for working diabetic patients are often
preferred, with experience suggesting only minor non-
attendance rates for evening DMO clinics. Messaging
beyond letter notiﬁcation could be considered to reinforce
the importance of a scheduled clinic appointment, for
instance with follow-up text messaging. Text messaging
can be quite effective for younger adults for example. For
DR screening programmes, the regular non-attenders
need to be vigorously chased.
Principle 5. Set realistic patient expectations when
initiating treatment of DMO. Adequate support should be
provided to ensure that patients understand the treatment
they are being given and why that particular treatment is
right for them, the treatment response they might expect,
the most common side effects and the options that might
be available if the initial treatment does not work well or
does not suit them.
Where the treatment choice for DMO is intravitreal ant-
VEGF therapy, patients should understand the goal of
treatment, the need for regular repeat therapy, the
treatment plan including follow-up regimen and be aware
also that the frequency of injections may diminish after
the ﬁrst year of treatment.
Table 7 Online sources of patient information and resources
K Diabetes
J Diabetes UK. The leading charity that cares for and campaigns for people affected by or at risk of diabetes.
J http://www.diabetes.org.uk/
J Following a change in measurement reporting of HbA1c, Diabetes UK has developed an easy-to-use online HbA1c converter,
for conversion of old (percentage units) and newer higher order measurements in millimoles per mol (mmol/mol).
J http://www.diabetes.org.uk/HbA1c
J Leicestershire Diabetes Service provides an extensive online diabetes resource.
J http://www.leicestershirediabetes.org.uk/
K Diabetic eye disease
J Moorﬁelds Eye Hospital NHS Foundation Trust. Facts about diabetic macular oedema. Patient information - medical retina
services. Authored by Ms Dawn Sam, revision number 4, May 2016.
J http://www.moorﬁelds.nhs.uk/sites/default/ﬁles/diabetic-macular-oedema.pdf
J The Macular Disease Society. Your guide to diabetic macular oedema. Macular Society 2015.
J http://www.macularsociety.org/sites/default/ﬁles/resource/Diabetic Macular Oedema.pdf
J Royal National Institute for the Blind (RNIB). Understanding eye conditions related to diabetes. RNIB and RCOphth July 2016.
Accredited by the Royal College of Ophthalmologists, this guide provides a detailed explanation of the eye and helpful advice
on next steps.
J http://www.rnib.org.uk/sites/default/ﬁles/Understanding_eye_conditions_related_to_Diabetes.pd_related_to_Diabetes.pdf
J NHS Public Health England. Your guide to diabetic retinopathy. Important information about signs of changes to your eyes
caused by diabetes. Public Health England.
J http://www.gov.uk/government/uploads/system/uploads/attachment_data/ﬁle/499568/DES_03_Your_guide_to_
diabetic_retinopathy_single_pages_090216.pdf
J NHS Public Health England. Closer monitoring and treatment for diabetic retinopathy. Public Health England.
J http://www.gov.uk/government/uploads/system/uploads/attachment_data/ﬁle/502429/DES_05_web_version_230216.pdf
J Further online information about diabetic eye screening and other aspects of diabetes care is available at http://www.nhs.uk/
diabeticeye
K Driving
J The Macular Disease Society. Driving. Everything you need to know about driving if you have macular disease. Also available
on audio CD. Macular Society 2016.
J http://www.macularsociety.org/sites/default/ﬁles/downloads/Macular Society Driving 0316.pdf
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Regular clinical attendance is required to resolve
macular oedema and to ensure maintenance and/or
improvement of vision long-term. Inadequate or delayed
treatment may result in irreversible vision loss. The
potential need for additional or substitute treatments
should be discussed at the outset as there may be some
cases of refractory macular oedema. Patients are
reminded of the need to be proactive in optimising
control of modiﬁable systemic risk factors. Several online
sources of patient information and resources are outlined
in Table 7.
Principle 6. Perform a regular audit of practice outcomes
and benchmark performance, preferably using an
electronic medical record (EMR) system. Audit and
benchmark the key performance indicators of efﬁcacy,
safety, and treatment burden in the management
and treatment of DMO. Development of a nationally
agreed DMO outcome data set for EMR reporting will
facilitate national audit data collection and shared
learning.
Best practice
Best practice models illustrate progress in strengthening
service capacity and referral reﬁnement of DR, including
the use of OCT imaging as a second-line surveillance tool
for evaluating referrals of screen-positive maculopathy.
Illustrative examples include:
K Reﬁnement of screening referrals. Consider establishing a
second-line surveillance service for screen-positive
maculopathy and/or pre-proliferative DR. OCT-
guided surveillance clinics for screen-positive maculo-
pathy and/or pre-proliferative DR provide additional
ﬂexibility in DMO management by helping minimise
or limit false positive referrals to the Hospital Eye
Service.82
K Evening technician-led imaging clinics. Evening
technician-led OCT imaging clinics for DMO patients
being treated with intravitreal anti-VEGF therapy
have been introduced successfully within ophthalmol-
ogy departments, uplifting capacity and allowing
high-speed decision-making based on ophthalmolo-
gist review of acquired OCT scans. This frees up
additional time for direct ophthalmologist review of
more complex cases and for patient cases that may
beneﬁt from a treatment switch.
K DSN-led reviews of initial referrals of background
DR or diabetic maculopathy after brief medical
history and fundoscopy carried out by the eye
clinic ophthalmologist, covering key baseline
diabetes investigations and onward referral to the
eye care service or discharge to primary care
diabetes care.
K Virtual review clinics utilising OCT imaging combined
with fundus photography. For patients with established
DMO on regular intravitreal treatment and follow-up,
a virtual OCT review clinic allows for separate
assessment and grading of OCT images and fundus
photographs by trained hospital technicians and
nurses. Patients with stable disease are taken out of
the existing DMO clinic service, releasing additional
front-line treatment capacity.
Conclusion
Findings from the Diabetic Retinopathy Clinical Research
Network (DRCR.net) reiterate that long-term success in
optimisation of glycaemic control as measured by HbA1c
can be challenging.83 Investigators from DRCR.net
identiﬁed a need for frequent educational interaction
and additional communication with local primary diabetes
care providers, as part of a comprehensive approach to the
management of vision loss due to DR and DMO.83 People
with diabetes need education to manage their condition
and need to be informed of the risks to their sight early in
the management of their diabetes care to ensure good
compliance with regular eye checks.
Greater collaboration between eye health profes-
sionals and general practitioners, practice nurses and
community-based diabetes care providers is
recommended in order to ensure better coordinated
follow-up and timely assessment of diabetes patients with
related eye disease. Broader utilisation of and access to
community-based diabetes care regimens can be expected
to improve standards of patient care, and contribute to
greater awareness of the need for improved glycaemic
control to reduce diabetes-related complications and
morbidity.
Evidence from randomised controlled trials supports
treatment of proliferative DR and DMO to prevent
progressive vision loss and imaging plays a valuable
role in surveillance.62 Diabetes specialist nurses can
help allay patient anxiety, reinforce knowledge of the
value of adherence to treatment regimens and encourage
appropriate health behaviours.
As an integral part of the patient pathway, ophthalmo-
logists and other healthcare professionals play a vital
role in disease management by encouraging and
educating patients with DR and/or DMO to achieve
important health targets, particularly for blood glucose
and blood pressure control, to reduce the risk of
progression of vascular complications and preserve visual
function.
Summary: Action on DMO: best practice principles.
K Foster closer working relationships between diabetes
management, general practitioners, and ophthalmol-
ogy specialties.
K Consider the beneﬁts of establishing a dedicated DMO
eye clinic service for management and follow-up
of patients with diabetic eye disease, for example,
facilitate integration of a DSN-led review service and
enhance efﬁciency of diabetes care.
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K Explore aspirations and opportunities to expand the
role of the DSN in the hospital eye clinic, with the
specialist nurse acting as the main hub between
ophthalmology, endocrinology, diabetology, and pri-
mary care services/support.
K Tailor clinical practice and follow-up initiatives to
improve treatment adherence in DMO.
K Set realistic patient expectations when initiating
treatment of DMO.
K Perform a regular audit of practice outcomes and bench-
mark performance, preferably using an EMR system.
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